Determination of pharmacodynamics of the new neuroleptic zetidoline by neuroendocrinologic, pharmaco-EEG, and psychometric studies: Part II.
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004569:Electroencephalography; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000494:pharmacology*; D009460:Neurologic Examination; D011388:Prolactin / Q000097:blood; D011594:Psychometrics; D011930:Reaction Time / Q000187:drug effects
D014150:Antipsychotic Agents; D007093:Imidazoles; C027277:zetidoline; D011388:Prolactin; D006220:Haloperidol